Signal detection using change point analysis in postmarket surveillance-Reference-Cited by-同舟云学术

Signal detection using change point analysis in postmarket surveillance

Published:2015-04-22 Issue:6 Volume:24 Page:663-668
ISSN:1053-8569
Container-title:Pharmacoepidemiology and Drug Safety
language:en
Short-container-title:Pharmacoepidemiol Drug Saf

Author:

Xu Zhiheng¹,Kass‐Hout Taha²,Anderson‐Smits Colin³,Gray Gerry¹

Affiliation:

1. Division of Biostatistics U.S. Food and Drug Administration Silver Spring MD USA

2. Chief Health Informatics Officer, Chief Technology Officer, Office of Informatics and Technology Innovation, Office of Operations, Office of the Commissioner U.S. Food and Drug Administration Silver Spring MD USA

3. Division of Epidemiology U.S. Food and Drug Administration Silver Spring MD USA

Publisher

Wiley

Subject

Pharmacology (medical),Epidemiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pds.3783

Reference18 articles.

1. Performance of Pharmacovigilance Signal-Detection Algorithms for the FDA Adverse Event Reporting System

2. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports

3. Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system;DuMouchel W;The Am Stat,1999

4. Proposed Statistical Methods for Signal Detection of Adverse Medical Device Events

5. Statistical Issues Involved in Medical Device Postmarketing Surveillance

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Monitoring Adverse Drug Events in Web Forums: Evaluation of a Pipeline and Use Case Study;Journal of Medical Internet Research;2024-06-18

2. Monitoring Adverse Drug Events in Web Forums: Evaluation of a Pipeline and Use Case Study (Preprint);2023-02-01

3. An open-source platform integrating emerging data sources to support multi-modal active pharmacovigilance;Frontiers in Drug Safety and Regulation;2023-01-19

4. Validation of CORE-MD PMS Support Tool: A Novel Strategy for Aggregating Information from Notices of Failures to Support Medical Devices’ Post-Market Surveillance;Therapeutic Innovation & Regulatory Science;2023-01-18

5. Identifying Actionability as a Key Factor for the Adoption of ‘Intelligent’ Systems for Drug Safety: Lessons Learned from a User-Centred Design Approach;Drug Safety;2021-10-21